Rational Application of Antipsychotics in Pregnancy

doi:10.12114/j.issn.1007-9572.2019.00.223

Abstract

Abstract: The effect of medication in pregnancy on maternal health and fetal growth and development has aroused wide concern.However，due to limits of medical ethics and other factors，it is difficult to conduct an in-depth scientific research on medication during pregnancy.Schizophrenia is a chronic mental disease whose prevalence rate is increasing year by year.In particular，it is highly prevalent in those aged 25-35 years old，and women of this age group are in the ‘right' age to have a baby.In addition，treating emotional disorders and other psychiatric disorders associated with pregnancy，also may involve the use of antipsychotics.Antipsychotics can affect the fetus through the placenta，cause perinatal syndrome，even severe fetal malformations，and may also affect long-term neurobehavior.Likewise，untreated mental symptoms also affect the pregnant woman and the fetus.Therefore，the safety and necessity of appropriate use of antipsychotics during pregnancy have become a clinical problem that needs to be solved urgently.This paper mainly discusses the rational application of antipsychotics in pregnancy，in order to provide help for clinicians in formulating medication treatment plan for mental disorders during pregnancy.

Key words: Pregnancy, Antipsychotic agents, Fetal development, Physiological effects of drugs

摘要： 妊娠期用药对于母体健康和胎儿生长发育的影响备受关注。然而妊娠期用药受伦理学等多方面因素的限制，难以进行科学的深入研究。精神分裂症是一种慢性精神疾病，患病率逐年上升，其高发年龄为25~35岁，同样也是女性的适宜生育年龄。此外，情感障碍等其他妊娠期精神障碍可能涉及抗精神病药物的使用。抗精神病药物可以通过胎盘对胎儿造成影响，如围生期综合征，重者可致胎儿畸形，对新生儿后期的神经行为也可能产生影响。未经治疗的精神症状本身也会对妊娠期妇女和胎儿造成影响，因此患有精神障碍的妇女妊娠期抗精神病药物应用的安全性及必要性成为临床治疗亟待解决的问题。本文主要就妊娠期抗精神病药物的合理应用进行详述，以期为临床医师制定妊娠期精神障碍的用药治疗方案提供帮助。

关键词: 妊娠, 抗精神病药, 胎儿发育, 药物生理作用

ZHAI Qian,ZHANG Guofu,LIU Min, et al. Rational Application of Antipsychotics in Pregnancy　[J]. Chinese General Practice, 2019, 22(30): 3701-3708. DOI: 10.12114/j.issn.1007-9572.2019.00.223.
翟倩,张国富,刘敏等. 妊娠期抗精神病药物的合理应用[J]. 中国全科医学, 2019, 22(30): 3701-3708. DOI: 10.12114/j.issn.1007-9572.2019.00.223.

References

［1］JONES I，CHANDRA P S，DAZZAN P，et al．Bipolar disorder，affective psychosis，and schizophrenia in pregnancy and the post-partum period［J］．Lancet，2014，384（9956）：1789-1799．DOI：10.1016/S0140-6736（14）61278-2.
［2］MAINA G，ROSSO G，AGUGLIA A，et al．Recurrence rates of bipolar disorder during the postpartum period：a study on 276 medication-free Italian women［J］．Arch Womens Ment Health，2014，17（5）：367-372．DOI：10.1007/s00737-013-0405-4.
［3］GALBALLY M，NGUYEN T N，SNELLEN M.Commentary on RANZCP clinical practice guidelines for the management of schizophrenia and related disorders［J］．Aust N Z J Psychiatry，2017，51（3）：289-290．DOI：10.1177/0004867416678457.
［4］WESSELOO R，KAMPERMAN A M，MUNK-OLSEN T，et al．Risk of postpartum relapse in bipolar disorder and postpartum psychosis：a systematic review and meta-analysis［J］．Am J Psychiatry，2016，173（2）：117-127．DOI：10.1176/appi.ajp.2015.15010124.
［5］HOGAN C S，FREEMAN M P.Adverse effects in the pharmacologic management of bipolar disorder during pregnancy［J］．Psychiatr Clin North Am，2016，39（3）：465-475．DOI：10.1016/j.psc.2016.04.007.
［6］TOSATO S，ALBERT U，TOMASSI S，et al．A systematized review of atypical antipsychotics in pregnant women：balancing between risks of untreated illness and risks of drug-related adverse effects［J］．J Clin Psychiatry，2017，78（5）：e477-489．DOI：10.4088/JCP.15r10483.
［7］TERRANA N，KOREN G，PIVOVAROV J，et al．Pregnancy outcomes following in utero exposure to second-generation antipsychotics：a systematic review and meta-analysis［J］．J Clin Psychopharmacol，2015，35（5）：559-565．DOI：10.1097/JCP.0000000000000391.
［8］EINARSON A，BOSKOVIC R.Use and safety of antipsychotic drugs during pregnancy［J］．J Psychiatr Pract，2009，15（3）：183-192．DOI：10.1097/01.pra.0000351878.45260.94.
［9］TOH S，LI Q，CHEETHAM T C，et al．Prevalence and trends in the use of antipsychotic medications during pregnancy in the US，2001—2007：a population-based study of 585，615 deliveries［J］．Arch Womens Ment Health，2013，16（2）：149-157．DOI：10.1007/s00737-013-0330-6.
［10］瞿胜，程丽娟.孕期服用抗精神病药物安全性的临床研究［J］．医学美学美容：中旬刊，2014（4）：219-220.
［11］廖雪梅，苏允爱，司天梅.孕期服用抗精神病药安全性的临床研究［J］．中华精神科杂志，2013，46（2）：122-125．DOI：10.3760/cma.j.issn.1006-7884.2013.02.019.
［12］卢逃涛，蒙华庆，傅一笑，等．非典型抗精神病药物在孕期的用药安全性［J］．四川精神卫生，2015，28（5）：467-469．DOI：10.11886/j.issn.1007-3256.2015.05.025.
［13］汪志良.常用精神药物在孕期的临床应用及其安全性［J］．中国神经精神疾病杂志，2013，39（11）：685-687．DOI：10.3936/j.issn.1002-0152.2013.10.013.
［14］WARD R M.Pharmacology of the maternal-placental-fetal-unit and fetal therapy［J］．Progress in Pediatric Cardiology，1996，5（2）：79-89．DOI：10.1016/1058-9813（96）00153-1．
［15］KIM J H，SCIALLI A R.Thalidomide：the tragedy of birth defects and the effective treatment of disease［J］．Toxicol Sci，2011，122（1）：1-6．DOI：10.1093/toxsci/kfr088.
［16］CATALIN BUHIMSCHI C.妊娠哺乳期用药指南［M］．孙路路，译.2版.北京：人民军医出版社，2014．
［17］司天梅.Maudsley精神科处方指南［M］．12版.北京：人民卫生出版社，2017．
［18］Food and Drug Administration，HHS.Content and format of labeling for human prescription drug and biological products；requirements for pregnancy and lactation labeling.Final rule［J］．Fed Regist，2014，79（233）：72063-72103.
［19］European Medicines Agency，EMA.Guideline on the exposure to medicinal products during pregnancy：need for post-authorisation data［EB/OL］．［2005-11-14］．http：//www.ema.europa.eu/docs/en_GB/documentlibrary/Regulatory_and_procedural_guideline/2009/11/WC500011303.pdf.
［20］MCALLISTER-WILLIAMS R H，BALDWIN D S，CANTWELL R，et al．British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception，in pregnancy and postpartum 2017［J］．J Psychopharmacol（Oxford），2017，31（5）：519-552．DOI：10.1177/0269881117699361.
［21］LARSEN E R，DAMKIER P，PEDERSEN L H，et al．Use of psychotropic drugs during pregnancy and breast-feeding［J］．Acta Psychiatr Scand Suppl，2015（445）：1-28．DOI：10.1111/acps.12479.
［22］CHISOLM M S，PAYNE J L.Management of psychotropic drugs during pregnancy［J］．BMJ，2016，532：h5918．DOI：10.1136/bmj.h5918.
［23］HASAN A，FALKAI P，WOBROCK T，et al．World Federation of Societies of Biological Psychiatry （WFSBP） Guidelines for Biological Treatment of Schizophrenia.Part 3：Update 2015 Management of special circumstances：depression，suicidality，substance use disorders and pregnancy and lactation［J］．World J Biol Psychiatry，2015，16（3）：142-170．DOI：10.3109/15622975.2015.1009163.
［24］SHARMA V，SHARMA S.Peripartum management of bipolar disorder：what do the latest guidelines recommend？［J］．Expert Rev Neurother，2017，17（4）：335-344．DOI：10.1080/14737175.2017.1243470.
［25］COUGHLIN C G，BLACKWELL K A，BARTLEY C，et al．Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy［J］．Obstet Gynecol，2015，125（5）：1224-1235．DOI：10.1097/AOG.0000000000000759.
［26］CUNNINGTON M C，WEIL J G，MESSENHEIMER J A，et al．
Final results from 18 years of the International Lamotrigine Pregnancy Registry［J］．Neurology，2011，76（21）：1817-1823．DOI：10.1212/WNL.0b013e31821ccd18.
［27］PARK Y，HUYBRECHTS K F，COHEN J M，et al．Antipsychotic medication use among publicly insured pregnant women in the United States［J］．Psychiatr Serv，2017，68（11）：1112-1119．DOI：10.1176/appi.ps.201600408.
［28］HUYBRECHTS K F，HERNáNDEZ-DíAZ S，PATORNO E，et al．Antipsychotic use in pregnancy and the risk for congenital malformations［J］．JAMA Psychiatry，2016，73（9）：938-946．DOI：10.1001/jamapsychiatry.2016.1520.
［29］ENNIS Z N，DAMKIER P.Pregnancy exposure to olanzapine，quetiapine，risperidone，aripiprazole and risk of congenital malformations.A systematic review［J］．Basic Clin Pharmacol Toxicol，2015，116（4）：315-320．DOI：10.1111/bcpt.12372.
［30］HABERMANN F，FRITZSCHE J，FUHLBRüCK F，et al．Atypical antipsychotic drugs and pregnancy outcome：a prospective，cohort study［J］．J Clin Psychopharmacol，2013，33（4）：453-462．DOI：10.1097/JCP.0b013e318295fe12.
［31］GENTILE S.A safety evaluation of aripiprazole for treating schizophrenia during pregnancy and puerperium［J］．Expert Opin Drug Saf，2014，13（12）：1733-1742．DOI：10.1517/14740338.2014.951325.
［32］GALBALLY M，SNELLEN M，POWER J.Antipsychotic drugs in pregnancy：a review of their maternal and fetal effects［J］．Ther Adv Drug Saf，2014，5（2）：100-109．DOI：10.1177/2042098614522682.
［33］KALLEN B.Drugs during pregnancy：methodological aspects［M］．NewYork：Springer，2016：232-235.
［34］TINKER S C，GILBOA S，REEFHUIS J，et al．Challenges in studying modifiable risk factors for birth defects［J］．Curr Epidemiol Rep，2015，2（1）：23-30．DOI：10.1007/s40471-014-0028-y.
［35］BELLET F，BEYENS M N，BERNARD N，et al．Exposure to aripiprazole during embryogenesis：a prospective multicenter cohort study［J］．Pharmacoepidemiol Drug Saf，2015，24（4）：368-380．DOI：10.1002/pds.3749.
［36］张云淑，司天梅，栗克清.中国十省市第一代及第二代抗精神病药使用现况调查［J］．中国心理卫生杂志，2012，26（10）：736-740．DOI：10.3969/j.issn.1000-6729.2012.10.004.
［37］HANNAH R S，ROTH S H，SPIRA A W.The effects of chlorpromazine and phenobarbital on vasculogenesis in the cerebellar cortex［J］．Acta Neuropathol，1982，57（4）：306-308.
［38］FARKAS V，FARKAS G.Teratogenic action of hyperemesis in pregnancy and of medication used to treat it［J］．Zentralbl Gynakol，1971，10（2）：325-330.
［39］DIAV-CITRIN O，SHECHTMAN S，ORNOY S，et al．Safety of haloperidol and penfluridol in pregnancy：a multicenter，prospective，controlled study［J］．J Clin Psychiatry，2005，66（3）：317-322.
［40］SLONE D，SISKIND V，HEINONEN O P，et al．Antenatal exposure to the phenothiazines in relation to congenital malformations，perinatal mortality rate，birth weight，and intelligence quotient score［J］．Am J Obstet Gynecol，1977，128（5）：486-488.
［41］CUOMO A，GORACCI A，FAGIOLINI A.Aripiprazole use during pregnancy，peripartum and lactation.A systematic literature search and review to inform clinical practice［J］．J Affect Disord，2018，228：229-237．DOI：10.1016/j.jad.2017.12.021.
［42］K?LLéN B，BORG N，REIS M.The use of central nervous system active drugs during pregnancy［J］．Pharmaceuticals （Basel），2013，6（10）：1221-1286．DOI：10.3390/ph6101221.
［43］PETERSEN I，MCCREA R L，SAMMON C J，et al．Risks and benefits of psychotropic medication in pregnancy：cohort studies based on UK electronic primary care health records［J］．Health Technol Assess，2016，20（23）：1-176．DOI：10.3310/hta20230.
［44］SADOWSKI A，TODOROW M，YAZDANI BROJENI P，et al．Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs：a cohort study［J］．BMJ Open，2013，3（7）：e003062．DOI：10.1136/bmjopen-2013-003062.
［45］WICHMAN C L.Atypical antipsychotic use in pregnancy：a retrospective review［J］．Arch Womens Ment Health，2009，12（1）：53-57．DOI：10.1007/s00737-008-0044-3.
［46］Centers for Disease Control and Prevention（CDC）．Update on overall prevalence of major birth defects—Atlanta，Georgia，1978—2005［J］．MMWR Morb Mortal Wkly Rep，2008，57（1）：1-5.
［47］DOLK H，LOANE M，GARNE E.The prevalence of congenital anomalies in Europe［J］．Adv Exp Med Biol，2010，686：349-364．DOI：10.1007/978-90-481-9485-8_20.
［48］KHOSHNOOD B，GREENLEES R，LOANE M，et al．Paper 2：EUROCAT public health indicators for congenital anomalies in Europe［J］．Birth Defects Res Part A Clin Mol Teratol，2011，91（Suppl 1）：S16-S22．DOI：10.1002/bdra.20776.
［49］COPPOLA D，RUSSO L J，KWARTA R F Jr，et al．Evaluating the postmarketing experience of risperidone use during pregnancy：pregnancy and neonatal outcomes［J］．Drug Saf，2007，30（3）：247-264．DOI：10.2165/00002018-200730030-00006.
［50］KOREN G.The effect of ascertainment bias in evaluating gestational antidepressant exposure［J］．J Popul Ther Clin Pharmacol，2011，18：e174-e175.
［51］GALBALLY M，FRAYNE J，WATSON S J，et al．Aripiprazole and pregnancy：a retrospective，multicentre study［J］．J Affect Disord，2018，238：593-596．DOI：10.1016/j.jad.2018.06.004.
［52］UGUZ F.Second-generation antipsychotics during the lactation period：a comparative systematic review on infant safety［J］．J Clin Psychopharmacol，2016，36（3）：244-252．DOI：10.1097/JCP.0000000000000491.
［53］MCKENNA K，KOREN G，TETELBAUM M，et al．Pregnancy outcome of women using atypical antipsychotic drugs：a prospective comparative study［J］．J Clin Psychiatry，2005，66（4）：444-449； quiz 546.
［54］KULKARNI J，WORSLEY R，GILBERT H，et al．A prospective cohort study of antipsychotic medications in pregnancy：the first 147 pregnancies and 100 one year old babies［J］．PLoS One，2014，9（5）：e94788．DOI：10.1371/journal.pone.0094788.
［55］PENG M，GAO K M，DING Y L，et al．Effects of prenatal exposure to atypical antipsychotics on postnatal development and growth of infants：a case-controlled，prospective study［J］．Psychopharmacology （Berl ），2013，228（4）：577-584．DOI：10.1007/s00213-013-3060-6.
［56］DEV V，KRUPP P.The side effects and safety of clozapine ［J］．Rev Contemp Pharmacother，1995，6（2）：197-208.
［57］BAZIRE S.Psychotropic drug directory［M］．Salisbury：Fivepin Limited，2005.
［58］BODéN R，LUNDGREN M，BRANDT L，et al．Antipsychotics during pregnancy：relation to fetal and maternal metabolic effects［J］．Arch Gen Psychiatry，2012，69（7）：715-721．DOI：10.1001/archgenpsychiatry.2011.1870.
［59］NEWHAM J J，THOMAS S H，MACRITCHIE K，et al．Birth weight of infants after maternal exposure to typical and atypical antipsychotics：prospective comparison study［J］．Br J Psychiatry，2008，192（5）：333-337．DOI：10.1192/bjp.bp.107.041541.
［60］SHAO P，OU J J，PENG M，et al．Effects of clozapine and other atypical antipsychotics on infants development who were exposed to as fetus：a post-hoc analysis［J］．PLoS One，2015，10（4）：e0123373．DOI：10.1371/journal.pone.0123373.
［61］GRIGORIADIS S，VONDERPORTEN E H，MAMISASHVILI L，et al．Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn：systematic review and meta-analysis［J］．BMJ，2014，348：f6932．DOI：10.1136/bmj.f6932.
［62］BRUNNER E，FALK D M，JONES M，et al．Olanzapine in pregnancy and breastfeeding：a review of data from global safety surveillance［J］．BMC Pharmacol Toxicol，2013，14：38．DOI：10.1186/2050-6511-14-38.
［63］VIGOD S N，GOMES T，WILTON A S，et al．Antipsychotic drug use in pregnancy：high dimensional，propensity matched，population based cohort study［J］．BMJ，2015，350：h2298．DOI：10.1136/bmj.h2298.
［64］S?RENSEN M J，KJAERSGAARD M I，PEDERSEN H S，et al．Risk of fetal death after treatment with antipsychotic medications during pregnancy［J］．PLoS One，2015，10（7）：e0132280．DOI：10.1371/journal.pone.0132280.
［65］BABU G N，DESAI G，TIPPESWAMY H，et al．Birth weight and use of olanzapine in pregnancy：a prospective comparative study［J］．J Clin Psychopharmacol，2010，30（3）：331-332．DOI：10.1097/JCP.0b013e3181db8734.
［66］GJERDEN P，BRAMNESS J G，TVETE I F，et al．The antipsychotic agent quetiapine is increasingly not used as such：dispensed prescriptions in Norway 2004—2015［J］．Eur J Clin Pharmacol，2017，73（9）：1173-1179．DOI：10.1007/s00228-017-2281-8.
［67］HáLFDáNARSON ó，ZO?GA H，AAGAARD L，et al．International trends in antipsychotic use：a study in 16 countries，2005—2014［J］．Eur Neuropsychopharmacol，2017，27（10）：1064-1076．DOI：10.1016/j.euroneuro.2017.07.001.
［68］COHEN L S，GóEZ-MOGOLLóN L，SOSINSKY A Z，et al．Risk of major malformations in infants following first-trimester exposure to quetiapine［J］．Am J Psychiatry，2018，175（12）：1225-1231．DOI：10.1176/appi.ajp.2018.18010098.
［69］SINGH K P，SINGH M K，SINGH M.Effects of prenatal exposure to antipsychotic risperidone on developmental neurotoxicity，apoptotic neurodegeneration and neurobehavioral sequelae in rat offspring［J］．Int J Dev Neurosci，2016，52：13-23．DOI：10.1016/j.ijdevneu.2016.05.006.
［70］ONKEN M，MICK I，SCHAEFER C.Paliperidone and pregnancy-an evaluation of the German Embryotox database［J］．Arch Womens Ment Health，2018，21（6）：657-662．DOI：10.1007/s00737-018-0828-z.
［71］WAKIL L，PEREA E，PENASKOVIC K，et al．Exacerbation of psychotic disorder during pregnancy in the context of medication discontinuation［J］．Psychosomatics，2013，54（3）：290-293．DOI：10.1016/j.psym.2012.07.003.
［72］PETERSEN I，MCCREA R L，OSBORN D J，et al．Discontinuation of antipsychotic medication in pregnancy：a cohort study［J］．Schizophr Res，2014，159（1）：218-225．DOI：10.1016/j.schres.2014.07.034.
［73］LARSEN E R，SARIC K.Pregnancy and bipolar disorder：the risk of recurrence when discontinuing treatment with mood stabilisers：a systematic review［J］．Acta Neuropsychiatr，2017，29（5）：259-266．DOI：10.1017/neu.2016.60.
［74］CITROME L.Oral paliperidone extended-release：chemistry，pharmacodynamics，pharmacokinetics and metabolism，clinical efficacy，safety and tolerability［J］．Expert Opin Drug Metab Toxicol，2012，8（7）：873-888．DOI：10.1517/17425255.2012.693160.

[1]	LI Qian, ZHANG Yunshu, YAN Baoping, WANG Jian, MA Yanjuan, WANG Yuan, QIN Yingjie, NA Long, REN Zhiyong, SUN Junwei, DENG Huaili, MA Hongjun, QU Xuehui, ZHOU Nan, SI Tianmei. Efficacy and Safety of Risperidone Microspheres for Injection (Ⅱ) in the Treatment of Patients with Acute Schizophrenia [J]. Chinese General Practice, 2023, 26(32): 4007-4012.
[2]	WANG Minghuan, LI Yuhong, YU Min, WANG Yougang, YU Qiaozhi, YANG Fangfang, YUAN Dehui, ZHANG Liu. Effect of Allostatic Load on Adverse Pregnancy Outcomes of Women in Late Pregnancy [J]. Chinese General Practice, 2023, 26(32): 4064-4069.
[3]	YUAN Dehui, LI Yuhong, XIONG Min, YU Min, MA Ruiliang, YANG Fangfang, YU Qiaozhi, WANG Minghuan. Status and Influencing Factors of Allostatic Load in Pregnant Women at Different Trimesters [J]. Chinese General Practice, 2023, 26(32): 4057-4063.
[4]	HUANG Taishuai, CHI Yan, HE Ping, HUANG Guolan, ZUO Yanli. Cost-effectiveness Analysis of GnRH Antagonist Protocol and Short-acting GnRH Agonist Long Protocol in Fresh Embryo Transfer Based on Propensity Score Matching [J]. Chinese General Practice, 2023, 26(30): 3809-3814.
[5]	CHE Guoyu, MA Aqin, YANG Lan, LI Jing, WANG Ling. Influence of Group Cognitive Behavioral Therapy on Pregnancy Outcomes among Pregnant Women with Gestational Diabetes Mellitus: a Propensity Score Matching Study [J]. Chinese General Practice, 2023, 26(24): 2968-2972.
[6]	YUAN Xianxian, WANG Jia, ZHANG Kexin, YANG Ruihua, ZHENG Wei, LI Guanghui. Association between Blood Lipid Levels and Macrosomia in Pregnant Women with Different Pre-pregnancy Body Mass Index [J]. Chinese General Practice, 2023, 26(24): 2973-2979.
[7]	ZHANG Li, ZHENG Wei, WANG Jia, YUAN Xianxian, HAN Weiling, HUANG Junhua, TIAN Zhihong, LI Guanghui. Comparison of Gestational Weight Gain and Pregnancy Outcomes in Chinese Women with Singleton Pregnancy Using Standard of Recommendation for Weight Gain during Pregnancy Period and Guidelines by the Institute of Medicine [J]. Chinese General Practice, 2023, 26(24): 2959-2967.
[8]	WANG Minghuan, LI Yuhong, YUAN Dehui, YU Min, HAN Baoliang, YU Qiaozhi, YANG Fangfang, ZHANG Qin. Correlation between Allostatic Load Level and Depression among Women in Early Pregnancy [J]. Chinese General Practice, 2023, 26(21): 2609-2613.
[9]	WANG Jingyu, HONG Shenda, HAN Fang, LIU Guoli. A Review of Recent Advances in Screening for Obstructive Sleep Apnea during Pregnancy [J]. Chinese General Practice, 2023, 26(20): 2555-2558,2566.
[10]	TIAN Meixiang, ZHANG Zhengyi. Standard Management of Hypertension During the Preparation for Pregnancy [J]. Chinese General Practice, 2023, 26(18): 2190-2194.
[11]	LIANG Puzhao, TIAN Zhentao, WU Yuyi. Interpretation of the Management of Nephrolithiasis in Pregnancy: Multi-disciplinary Guidelines from an Academic Medical Center: Improving the Diagnostic and Therapeutic Capacity, and Strengthening Multi-disciplinary Collaborative Management [J]. Chinese General Practice, 2023, 26(05): 519-524.
[12]	WANG Boya, HE Yingming, XUE Yinshuang, XIANG Huifen. Factors Associated with the Outcomes of Preimplantation Genetic Testing in Assisted Reproduction [J]. Chinese General Practice, 2023, 26(02): 160-167.
[13]	DENG Chenqian, BAN Jiangli, CHEN Shuchun. Interpretation of ESE Clinical Practice Guideline on Functioning and Non-functioning Pituitary Adenomas in Pregnancy [J]. Chinese General Practice, 2022, 25(36): 4491-4495.
[14]	Na LI, Wenli CHENG. Timing of Antihypertensive Initiation in Gestational Hypertension—Early Intervention Can Reducec Clinical Risk [J]. Chinese General Practice, 2022, 25(30): 3733-3738.
[15]	Wen HUA, Lijun ZHANG, Sha LU, Jiahui XU, Nisile Kakongoma, Wensheng HU. Association of Weight Gain Rate in Second and Third Trimesters with Pregnancy Complications and Delivery Outcomes in Women with Gestational Diabetes Mellitus [J]. Chinese General Practice, 2022, 25(29): 3621-3626.